Literature DB >> 32239775

Orofacial Strength and Voice Quality as Outcome of Levodopa Challenge Test in Parkinson Disease.

Jérôme R Lechien1,2,3,4, Bertil Delsaut2,5, Anissa Abderrakib2,5, Kathy Huet2, Veronique Delvaux2, Myriam Piccaluga2, Mohamad Khalife3, Bernard Harmegnies2, Sven Saussez1,3,4, Serge Blecic5.   

Abstract

OBJECTIVE: To assess the usefulness of orofacial strength and voice quality as assessment of response to levodopa challenge test (LCT) used in the diagnosis of early idiopathic Parkinson disease (IPD). STUDY
DESIGN: Controlled Prospective Study.
METHODS: From January 2014 to April 2019, patients with early IPD and healthy individuals were recruited and evaluated for clinical findings (Hoehn and Yahr scale; Unified Parkinson's Disease Rating Scale); Voice Handicap Index (VHI); grade of dysphonia, roughness, breathiness, asthenia, and strain and instability (GRBASI); maximal phonation time; phonation quotient; acoustic parameters; and orofacial muscle strength Oral Performance Instrument (IOPI; IOPI Medical, Woodinville, WA, USA) t) at baseline and 45 minutes after the levodopa intake (LCT).
RESULTS: A total of 32 IPD patients and 20 healthy individuals completed the study. Healthy individuals exhibited better VHI, grade of dysphonia, breathiness, asthenia, strain, instability, and acoustic measurements (noise-related, tremor, F0 short- and mid-term and intensity short-term parameters) than healthy subjects. The mean values of muscle strength of lips, cheeks, fundamental frequency (F0), highest F0, and shimmer significantly improved from pre- to post-LCT in IPD patients. Healthy individuals did not exhibit significant changes of orofacial strength and voice quality assessment from pre- to post-LCT. Significant associations were found between clinical, orofacial strength, and some aerodynamic and acoustic measurements.
CONCLUSION: Orofacial strength and acoustic voice quality measurements may be used as objective outcomes of the LCT responsiveness in patients with early IPD. LEVEL OF EVIDENCE: 3A. Laryngoscope, 2020.
© 2020 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Parkinson; acoustic; aerodynamic; levodopa; movement; muscle; speech; strength; voice

Year:  2020        PMID: 32239775     DOI: 10.1002/lary.28645

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  1 in total

1.  Voice in Parkinson's Disease: A Machine Learning Study.

Authors:  Antonio Suppa; Giovanni Costantini; Francesco Asci; Pietro Di Leo; Mohammad Sami Al-Wardat; Giulia Di Lazzaro; Simona Scalise; Antonio Pisani; Giovanni Saggio
Journal:  Front Neurol       Date:  2022-02-15       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.